Government Plans to Cap Drug Prices at First Point of Sale
The government is considering a proposal to make essential medicines more affordable by capping prices at the first ‘point of sale’ rather than retail price, according to a report in the Economic Times newspaper. The move is intended to curb margins offered to hospitals, distributors and doctors to push particular brands.
In a proposal submitted to the Prime Minister’s Office, Niti Aayog suggested tweaking the current price fixation mechanism “to check exorbitant prices” of essential medicines. Market and institutional data such as costs at central, state and private hospitals will be used to arrive at ceiling prices.
At present, the government caps prices of essential drugs based on the average ‘price to retailer’ of all brands of any particular medicine with at least 1% market share. This price includes all trade margins, except for the retailer margin, which is fixed at 16% and added to the ceiling price to arrive at an MRP.
While the wholesaler’s margin is also fixed at 8% under the current pricing mechanism, it is usually not closely monitored as it is inbuilt in the ‘price to retailer’ – used for calculating ceiling price which, Niti Aayog says, is an opaque procedure that lends to profiteering.
Niti Aayog proposed to use ‘average price at the first point of sale’, or price to the stockist, wholesaler, distributor or hospital for calculation of ceiling price and fixing a total trade margin of 24%, which can be added to the ceiling price to arrive at MRP.
Drug-makers currently have the leeway to change prices by tweaking trade margins given to distributors and retailers. This also includes hefty expenses on marketing and promoting drug brands among hospitals and doctors.
Currently, the government directly controls prices of over 850 essential medicines by capping their prices. Around 17% of the more than Rs. 1-lakh crore domestic pharmaceutical market is under direct government price control. By volume, the government regulates 24% of all medicines sold.
2026-07-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India's PV Community Comes Together at the 6th Edition Drug Safety Symposium 2026 – India Chapter to Shape the Future of Patient Safety
-
6th Drug Safety Symposium 2026 to Focus on “Beyond Algorithms & Assumptions, What Actually Matters in Pharmacovigilance”
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Price Increases Sweep Chemical Industry, Both Overseas and Domestic Markets Experience Upward Trend
-
Major Strike! Raw Material Prices Surge by 11%!
-
Dow rises!
-
In April, the first round of price increases hit!
-
Chemical market slightly back
-
China's pesticide price index in October 2022
-
Today's US dollar market PTA price fell
Recommend Reading
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
-
China’s Chemical “Spring Surge”: 68.8% of Products Rising—Real Recovery or Just a Pre-Festival Mirage?
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
Metso Expands Wear Parts Capacity in China with New Rubber Factory in Quzhou
-
TDI Supply Tightens and Prices Surge: Can Cangzhou Dahua Reap the "Chemical Dividend"?
-
Double Benefits: Aniline Market Rises Multiple Times
-
ECHEMI High Quality Inquiries (2-6 Aug)
-
Rise in Chinese Urea Market Prices (1.12-1.16)
-
Bullish and Bearish Battles, Palm Oil Prices Fluctuate
-
Lithium Carbonate Prices Under Pressure and Falling